A glabridin composition with high skin permeability and its preparation method and application

By preparing the photolicorice pyrrhizine composition containing oil and surfactant, the application of photolicorice pyrrhizine in cosmetics is solved, its permeability and stability are improved, the preparation cost is reduced, the operation is simplified, and efficient whitening and freckle removal is achieved. Effect.

CN118557453BActive Publication Date: 2024-12-03GUANGZHOU FANZHIRONG COSMETICS CO LTD +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411035288.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-12-03
Estimated Expiration
2044-07-31

AI Technical Summary

Technical Problem

The use of existing photolicorice in cosmetics is limited by its insoluble in water, low permeability, poor stability, high irritation, high preparation cost and complex operation, and existing carrier technologies such as cyclodextrin and phospholipid packages There is a sticky feeling, precipitation problems and drug stability.

Method used

Using photolicoricide compositions prepared from oils, 3-o-ethyl ascorbic acid, anionic surfactant, nonionic surfactant, polyol and water, gels are formed through specific mixing and heating dissolution steps to increase their skin penetration. and stability, using simple processes to reduce preparation costs.

Benefits of technology

The transdermal rate, solubility, stability and safety of the photolicoricide composition is improved, the preparation cost is reduced, the operation process is simplified, and its state stability and pH stability under high and low temperature conditions are enhanced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention provides a glabridin composition with high skin permeability and its preparation method and application, belonging to the field of cosmetics. The glabridin composition is prepared by S1 phase, S2 phase and S3 phase, the S1 phase is composed of oil and glabridin, the S2 phase is prepared by 3-o-ethyl ascorbic acid, anionic surfactant, nonionic surfactant, polyol and water, and the S3 phase is water. The glabridin composition is prepared by conventional emulsification equipment, with low preparation cost and simple operation process. The composition has good skin permeability, good state stability, good content stability, good pH stability under high and low temperature conditions, and high mildness, with unexpected technical effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of cosmetics, and in particular to a glabridin composition with high skin permeability, a preparation method and application thereof. Background Art

[0002] Glabridin, commonly known as "whitening gold", can effectively inhibit the activity of tyrosinase, inhibit dopachrome interconversion, inhibit the activity of DHICA oxidase and inhibit the activity of pigment cytochrome P450 3A4 enzyme (abbreviated as CYP3A4), thereby achieving the purpose of efficient and green whitening and freckle removal. However, due to the insolubility of glabridin in water and its low permeability, its application in formulas is limited.

[0003] Glabridin is a fat-soluble active substance that dissolves in polyols, is slightly soluble in oils and fats, and is insoluble in water. Therefore, in order to improve the ability of glabridin to penetrate the skin, it is necessary to solve the problem of glabridin's solubility, and to use carrier technologies such as microencapsulation, liposomes, and nanoemulsions to encapsulate the active ingredients and carry glabridin to penetrate the stratum corneum of the skin to improve permeability. However, if the conventional preparation method and formula composition are used, there are technical problems such as low skin penetration rate, low solubility of glabridin, poor stability, high irritation, high preparation cost, and complex operation.

[0004] The prior art provides a method for encapsulating glabridin with cyclodextrin, such as preparing cyclodextrin inclusion compounds by precipitation, grinding, freeze drying, spray drying and other techniques. These techniques require the use of equipment that is not commonly used in cosmetic production, and cyclodextrin has a large molecular weight and is hydrophilic on the outside, which greatly weakens the ability of the active substance to directly penetrate the hydrophobic stratum corneum. In addition, in the formulation of skin care products, the cyclodextrin encapsulation system has two drawbacks. One is that the cyclodextrin itself feels very sticky, which will cause consumers to have an unpleasant sticky feeling during use. The other is that the cyclodextrin encapsulation system is prone to crystallization in the formula. Literature shows that polyols such as pentanediol and hexanediol will affect the encapsulation stability of cyclodextrin, causing difficulties for formulators in the development of cosmetic formulas.

[0005] The prior art also provides a method for phospholipid inclusion of glabridin, in which the phospholipid inclusion complex is prepared by thin film rehydration method, reverse phase evaporation method, injection method, microfluidics method and other technologies, which also require the use of equipment that is not commonly used in cosmetic production. In addition, the liposomes may aggregate, leak or change their structure during storage, resulting in the loss or premature release of active substances. The phospholipases in the body can decompose the liposomes, directly affecting the drug delivery efficiency and controlled release characteristics.

[0006] Therefore, there is still an urgent need for a glabridin composition with high skin penetration rate, good solubility, good stability, good skin feel, low irritation, low preparation cost and simple operation process. Summary of the invention SUMMARY OF THE INVENTION

[0008] In order to provide a glabridin composition with high skin penetration rate, good solubility, no crystallization during stability, good content stability, good pH stability, high mildness, good skin feel, low preparation cost and simple operation process, the present invention provides the following technical scheme.

[0009] In a first aspect, the present invention provides a glabridin composition, wherein the glabridin is prepared from an S1 phase, an S2 phase and an S3 phase, wherein the S1 phase is composed of oil and glabridin, the S2 phase is prepared from 3-o-ethyl ascorbic acid, an anionic surfactant, a nonionic surfactant, a polyol and water, and the S3 phase is water;

[0010] The nonionic surfactant is oleth-20 and polyglyceryl-10 oleate; the anionic surfactant is sodium stearoyl glutamate; the oil is caprylic / capric triglyceride; the polyol is 1,3-butylene glycol;

[0011] Calculated based on the total mass of the glabridin composition, the content of the glabridin is 0.10wt%-4.00wt%, the content of the 3-o-ethyl ascorbic acid is 0.10wt%-4.00wt%; the total content of the nonionic surfactant is 0.70wt%-10.00wt%, the content of the oil is 1.00wt%-40.00wt%; the content of the polyol is 0.60wt%-6.00wt%, the content of the anionic surfactant is 0.10wt%-1.00wt%, the content of water in the S2 phase is 0.30wt%-3.00wt%, and the balance is the S3 phase;

[0012] In addition, the present invention also provides a method for preparing the glabridin composition.

[0013] The technical solution of the present invention is beneficial to improving the skin permeability and solubility of the glabridin composition, and is beneficial to improving its state stability, content stability, pH stability and mildness under high and low temperature conditions, and has unexpected technical effects.

[0014] The preparation method provided by the present invention does not require the use of non-commonly used equipment for cosmetic production, and can be prepared by simple process operation, which is beneficial to improving the skin permeability and solubility of the glabridin composition, and is beneficial to improving its state stability, content stability, pH stability, and mildness under high and low temperature conditions.

[0015] In a second aspect, the present invention provides a use of the glabridin composition described in the first aspect in preparing cosmetics.

[0016] In a third aspect, the present invention provides a cosmetic comprising the glabridin composition according to the first aspect. DETAILED DESCRIPTION OF THE INVENTION

[0018] In order to solve the above technical problems, the present invention provides a glabridin composition and a preparation method thereof.

[0019] In a first aspect, the present invention provides a glabridin composition.

[0020] A glabridin composition, the glabridin composition is prepared from an S1 phase, an S2 phase and an S3 phase, the S1 phase is composed of oil and glabridin, the S2 phase is prepared from 3-o-ethyl ascorbic acid, an anionic surfactant, a nonionic surfactant, a polyol and water, and the S3 phase is water;

[0021] The nonionic surfactants are oleth-20 and polyglycerol-10 oleate;

[0022] The anionic surfactant is sodium stearoyl glutamate;

[0023] The oil is caprylic / capric triglyceride;

[0024] The polyol is 1,3-butanediol;

[0025] Calculated based on the total mass of the glabridin composition, the content of the glabridin is 0.10wt%-4.00wt%, the content of the 3-o-ethyl ascorbic acid is 0.10wt%-4.00wt%; the total content of the nonionic surfactant is 0.70wt%-10.00wt%, the content of the oil is 1.00wt%-40.00wt%; the content of the polyol is 0.60wt%-6.00wt%, the content of the anionic surfactant is 0.10wt%-1.00wt%, the content of water in the S2 phase is 0.30wt%-3.00wt%, and the balance is the S3 phase;

[0026] The preparation method of the glabridin composition comprises the following steps:

[0027] (1) Mix glabridin and oil, heat to dissolve, and mix evenly to obtain S1 phase;

[0028] (2) Mix 3-o-ethyl ascorbic acid, anionic surfactant, nonionic surfactant, polyol and water, heat to dissolve, and mix evenly to obtain S2 phase;

[0029] (3) While stirring the S2 phase, adding the S1 phase obtained in step (1) to the S2 phase obtained in step (2), mixing, and forming a gel;

[0030] (4) The gel obtained in step (3) is mixed with S3 to obtain the glabridin composition.

[0031] In some embodiments, based on the total mass of the glabridin composition, the content of oleth-20 is 0.10 wt %-4.00 wt %, and the content of polyglycerol-10 oleate is 0.60 wt %-6.00 wt %.

[0032] In some embodiments, calculated based on the total mass of the glabridin composition, the content of the glabridin is 1.00wt%-4.00wt%, the content of the 3-o-ethyl ascorbic acid is 1.00wt%-4.00wt%; the content of the oleth-20 is 0.50wt%-4.00wt%, the content of the polyglycerol-10 oleate is 6.00 wt%, the content of the oil is 10.00wt%-40.00wt%; the content of the polyol is 6.00wt%, the content of the anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase.

[0033] In some embodiments, calculated based on the total mass of the glabridin composition, the content of the glabridin is 0.10wt%, the content of the 3-o-ethyl ascorbic acid is 0.10wt%; the content of the oleth-20 is 0.10wt%, the content of the polyglycerol-10 oleate is 0.60wt%, the content of the oil is 1.00wt%; the content of the polyol is 0.60wt%, the content of the anionic surfactant is 0.10wt%, the content of water in the S2 phase is 0.30wt%, and the balance is the S3 phase.

[0034] In some embodiments, calculated based on the total mass of the glabridin composition, the content of the glabridin is 1.00wt%, the content of the 3-o-ethyl ascorbic acid is 1.00wt%; the content of the oleth-20 is 0.50wt%, the content of the polyglycerol-10 oleate is 6.00wt%, the content of the oil is 10.00wt%; the content of the polyol is 6.00wt%, the content of the anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase.

[0035] In some embodiments, calculated based on the total mass of the glabridin composition, the content of the glabridin is 1.00wt%, the content of the 3-o-ethyl ascorbic acid is 1.00wt%; the content of the oleth-20 is 1.00wt%, the content of the polyglycerol-10 oleate is 6.00wt%, the content of the oil is 10.00wt%; the content of the polyol is 6.00wt%, the content of the anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase.

[0036] In some embodiments, calculated based on the total mass of the glabridin composition, the content of the glabridin is 1.00wt%, the content of the 3-o-ethyl ascorbic acid is 2.00wt%; the content of the oleth-20 is 0.50wt%, the content of the polyglycerol-10 oleate is 6.00wt%, the content of the oil is 10.00wt%; the content of the polyol is 6.00wt%, the content of the anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase.

[0037] In some embodiments, calculated based on the total mass of the glabridin composition, the content of the glabridin is 2.00wt%, the content of the 3-o-ethyl ascorbic acid is 2.00wt%; the content of the oleth-20 is 2.00wt%, the content of the polyglycerol-10 oleate is 6.00wt%, the content of the oil is 20.00wt%; the content of the polyol is 6.00wt%, the content of the anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase.

[0038] In some embodiments, calculated based on the total mass of the glabridin composition, the content of the glabridin is 4.00wt%, the content of the 3-o-ethyl ascorbic acid is 4.00wt%; the content of the oleth-20 is 4.00wt%, the content of the polyglycerol-10 oleate is 6.00wt%, the content of the oil is 40.00wt%; the content of the polyol is 6.00wt%, the content of the anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase.

[0039] In some embodiments, the heating and dissolving in step (1) is heating to 60°C-80°C for dissolving. In some embodiments, the heating and dissolving in step (1) is heating to 60°C, 65°C, 70°C, 75°C or 80°C for dissolving.

[0040] In some embodiments, the heating and dissolving in step (2) is heating to 60°C-70°C for dissolving. In some embodiments, the heating and dissolving in step (2) is heating to 60°C, 65°C or 70°C for dissolving.

[0041] In some embodiments, the heating to dissolve in step (1) is heating to 70°C for dissolving; and the heating to dissolve in step (2) is heating to 60°C for dissolving.

[0042] In some embodiments, the mass ratio of water to polyol in step (2) is 1:1-1:2.

[0043] In a second aspect, the present invention provides a use of the glabridin composition described in the first aspect.

[0044] A use of the glabridin composition of the first aspect in preparing cosmetics.

[0045] In a third aspect, the present invention provides a cosmetic.

[0046] A cosmetic comprising the glabridin composition according to the first aspect.

[0047] In some embodiments, the cosmetic is in the form of an essence.

[0048] In some embodiments, the cosmetic is an essence dosage form, and the cosmetic includes phase A, phase B, phase C, phase D, phase E and phase F; the phase A includes water, disodium EDTA and carbomer; the phase B includes parahydroxyacetophenone, 1,2-pentanediol and 1,2-hexanediol; the phase C includes water and arginine; the phase D includes hydrogenated lecithin, ethoxydiglycol, palmitoyl tripeptide-8 and α-tocopherol; the phase E includes glutathione and a plant extract aqueous solution; the phase F is the glabridin composition described in the first aspect.

[0049] In some embodiments, the aqueous plant extract solution is peony flower water.

[0050] In some embodiments, based on the total mass of the cosmetic, the content of the F phase is 1.000wt%-2.000wt%; the content of glutathione in the E phase is 0.001wt%-0.050wt%; the content of peony water in the E phase is 0.050wt%-0.500wt%; the content of hydrogenated lecithin in the D phase is 0.040 wt%-0.100wt%; the content of ethoxydiglycol in the D phase is 0.010wt%-0.100wt%; the content of palmitoyl tripeptide-8 in the D phase is 0.001 wt%-0.005wt%; the content of α-tocopherol in the D phase is 0.005 wt%-0.010wt%; the water content of the C phase is 1.000wt%-2.000wt%; the arginine content of the C phase is 0.100wt%-0.500wt%; the p-hydroxyacetophenone content of the B phase is 0.050 wt%-0.300wt%; the 1,2-pentanediol content of the B phase is 1.000wt%-5.000wt%; the 1,2-hexanediol content of the B phase is 0.500wt%-1.000wt%; the EDTA disodium content of the A phase is 0.020wt%-0.100wt%; the carbomer content of the A phase is 0.100wt%-0.500wt%; and the balance is water of the A phase.

[0051] In some embodiments, based on the total mass of the cosmetic, the content of the F phase is 1.000wt%; the content of glutathione in the E phase is 0.010wt%; the content of peony flower water in the E phase is 0.100wt%; the content of hydrogenated lecithin in the D phase is 0.060wt%; the content of ethoxydiglycol in the D phase is 0.020wt%; the content of palmitoyl tripeptide-8 in the D phase is 0.002wt%; the content of α-tocopherol in the D phase is 0.005wt%; the content of water in the C phase is 1.000wt%; the content of arginine in the C phase is 0.200wt%; the content of p-hydroxyacetophenone in the B phase is 0.100wt%; the content of 1,2-pentanediol in the B phase is 3.000wt%; the content of 1,2-hexanediol in the B phase is 0.500wt%; the EDTA in the A phase is 1.000wt%. The content of disodium is 0.050wt%; the content of carbomer in phase A is 0.200wt%; and the balance is water in phase A.

[0052] In some embodiments, based on the total mass of the cosmetic, the content of the F phase is 2.000wt%; the content of glutathione in the E phase is 0.050wt%; the content of peony water in the E phase is 0.500wt%; the content of hydrogenated lecithin in the D phase is 0.100wt%; the content of ethoxydiglycol in the D phase is 0.100wt%; the content of palmitoyl tripeptide-8 in the D phase is 0.005wt%; the content of α-tocopherol in the D phase is 0.010wt%; the content of water in the C phase is 2.000wt%; the content of arginine in the C phase is 0.500wt%; the content of p-hydroxyacetophenone in the B phase is 0.300wt%; the content of 1,2-pentanediol in the B phase is 5.000wt%; the content of 1,2-hexanediol in the B phase is 1.000wt%; the EDTA in the A phase is 1.000wt%. The content of disodium is 0.100wt%; the content of carbomer in phase A is 0.500wt%; and the balance is water in phase A.

[0053] In some embodiments, based on the total mass of the cosmetic, the content of the F phase is 1.000wt%; the content of glutathione in the E phase is 0.001wt%; the content of peony flower water in the E phase is 0.050wt%; the content of hydrogenated lecithin in the D phase is 0.040wt%; the content of ethoxydiglycol in the D phase is 0.010wt%; the content of palmitoyl tripeptide-8 in the D phase is 0.001wt%; the content of α-tocopherol in the D phase is 0.005wt%; the content of water in the C phase is 1.000wt%; the content of arginine in the C phase is 0.100wt%; the content of p-hydroxyacetophenone in the B phase is 0.050wt%; the content of 1,2-pentanediol in the B phase is 1.000wt%; the content of 1,2-hexanediol in the B phase is 0.500wt%; the EDTA in the A phase is 0.000wt%. The content of disodium is 0.020wt%; the content of carbomer in phase A is 0.100wt%; and the balance is water in phase A.

[0054] In some embodiments, the cosmetic is in the form of an essence, and the preparation method of the cosmetic comprises:

[0055] (i) Mix the components in phase A, heat to dissolve, and then cool to 40°C-50°C to obtain phase A;

[0056] (ii) mixing the components in phase B, heating to dissolve, and then cooling to room temperature to obtain phase B;

[0057] (iii) stirring the components in phase C until they are completely dissolved to obtain phase C;

[0058] (iv) mixing and stirring the components in phase D, heating to 65°C-75°C, and homogenizing to obtain phase D;

[0059] (v) While stirring phase A, phases B, C, D, E and F are added to phase A obtained in step (i) and mixed to obtain the cosmetic.

[0060] In some embodiments, the heating and dissolving in step (i) is heating to 75°C-85°C, keeping warm for 5 minutes-40 minutes, and stirring until completely dissolved. In some embodiments, the heating and dissolving in step (i) is heating to 75°C, 80°C or 85°C, keeping warm for 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes or 40 minutes, and stirring until completely dissolved.

[0061] In some embodiments, the cooling in step (i) is cooling to 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C or 50°C.

[0062] In some embodiments, the heating and dissolving in step (ii) is heating to 60°C-70°C and stirring until completely dissolved. In some embodiments, the heating and dissolving in step (ii) is heating to 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C or 70°C and stirring until completely dissolved.

[0063] In some embodiments, the normal temperature in step (ii) is 20°C-35°C. In some embodiments, the normal temperature in step (ii) is 25°C-30°C.

[0064] In some embodiments, the heating to 65°C-75°C in step (iv) is heating to 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, or 75°C.

[0065] In some embodiments, the homogenization speed of the homogenization in step (iv) is 1500 rpm-2500 rpm. In some embodiments, the homogenization speed of the homogenization in step (iv) is 1500 rpm, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400 or 2500 rpm.

[0066] In some embodiments, the homogenization time in step (iv) is 5 minutes to 30 minutes. In some embodiments, the homogenization time in step (iv) is 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes or 30 minutes.

[0067] Beneficial Effects

[0068] Compared with the prior art, the technical solution provided by the present invention has at least one of the following beneficial technical effects:

[0069] (1) Compared with a formulation lacking any of the components of 3-o-ethyl ascorbic acid, polyols, nonionic surfactants, and anionic surfactants, the glabridin composition provided by the present invention is more conducive to improving the permeability of the essence dosage form and has unexpected technical effects.

[0070] (2) Compared with other preparation methods (for example, the order of adding 3-o-ethyl ascorbic acid is different), the glabridin composition obtained by the preparation process provided by the present invention is more conducive to improving the permeability of the essence dosage form and has unexpected technical effects.

[0071] (3) Compared with cyclodextrin inclusion and liposome inclusion, the glabridin composition obtained by the preparation process provided by the present invention is more conducive to improving the permeability of the essence dosage form and has unexpected technical effects.

[0072] (4) Compared with other nonionic surfactants, the glabridin composition obtained by using oleth-20 and polyglycerol-10 oleate as nonionic surfactants in the present invention is more conducive to improving the permeability of the essence dosage form, and has unexpected technical effects.

[0073] (5) Compared with other polyols, the glabridin composition obtained by using 1,3-butanediol as the polyol in the present invention is more conducive to improving the permeability of the essence dosage form, and has unexpected technical effects.

[0074] (6) Compared with other oils, the glabridin composition obtained by using caprylic acid / capric acid triglyceride as the oil in the present invention is more conducive to improving the permeability of the essence dosage form, and has unexpected technical effects.

[0075] (7) Compared with the composition without adding 3-o-ethyl ascorbic acid, the glabridin composition provided by the present invention is more conducive to improving the onset rate and effect of the clinical whitening and freckle removal effect of the essence dosage form, and has unexpected technical effects;

[0076] (8) Compared with other preparation methods (for example, the order of adding 3-o-ethyl ascorbic acid is different), the glabridin composition obtained by the preparation process provided by the present invention is more conducive to improving the onset rate and effect of the clinical whitening and freckle removal effect of the essence dosage form, and has unexpected technical effects.

[0077] (9) Compared with cyclodextrin inclusion and liposome inclusion, the glabridin composition obtained by the preparation process provided by the present invention is more conducive to improving the onset rate and effect of the clinical whitening and freckle removal efficacy of the essence dosage form, and has unexpected technical effects.

[0078] (10) Compared with a formulation lacking any of the components of 3-o-ethyl ascorbic acid, polyols, nonionic surfactants, and anionic surfactants, the formulation provided by the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high and low temperature conditions.

[0079] (11) Compared with other nonionic surfactants, the use of oleth-20 and polyglycerol-10 oleate in the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high and low temperature conditions.

[0080] (12) Compared with other polyols, the use of 1,3-butanediol in the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high temperature conditions.

[0081] (13) Compared with other oils, the use of caprylic acid / capric acid triglyceride in the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high temperature conditions.

[0082] (14) Compared with other anionic surfactants, the use of sodium stearoyl glutamate in the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high and low temperature conditions.

[0083] (15) Compared with other preparation methods (for example, different addition orders of 3-o-ethyl ascorbic acid or water), the preparation process provided by the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high and low temperature conditions.

[0084] (16) Compared with other preparation methods (for example, a different order of adding 3-o-ethyl ascorbic acid), the preparation process provided by the present invention is more conducive to improving the pH stability of the glabridin composition under high and low temperature conditions.

[0085] (17) Compared with not adding 3-o-ethyl ascorbic acid, the formula provided by the present invention is more conducive to improving the safety of the glabridin composition and has unexpected technical effects.

[0086] (18) Compared with other preparation methods (for example, a different order of adding 3-o-ethyl ascorbic acid), the preparation process provided by the present invention is more conducive to improving the safety of the glabridin composition.

[0087] (19) The preparation method of the glabridin composition provided by the present invention is simple, and the required equipment is simple and all of them are conventional equipment in the cosmetics field. There is no need to use equipment that is not commonly used in cosmetics production, which is conducive to reducing the preparation cost.

[0088] Terminology

[0089] In the above text of the present invention, regardless of whether the words "about" or "approximately" are used, all the numbers disclosed herein are approximate values. Based on the disclosed numbers, the value of each number may vary by less than ±10% or reasonable differences considered by those skilled in the art, such as ±1%, ±2%, ±3%, ±4% or ±5%.

[0090] The term "normal temperature" refers to the indoor ambient temperature, which is 20℃-35℃, or 25℃-30℃.

[0091] The term "and / or" should be understood to mean any one of the optional items or a combination of any two or more of the optional items.

[0092] The term "wt%" means percent by mass.

[0093] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction. DETAILED DESCRIPTION

[0094] In order to enable those skilled in the art to better understand the technical solution of the present invention, some non-limiting embodiments are further disclosed below to further illustrate the present invention in detail.

[0095] The reagents used in the present invention can be purchased from the market or prepared by the method described in the present invention.

[0096] 1. Test method for glabridin content

[0097] The test method for glabridin content refers to Q / FZR 0101-2023 "Glycyrrhizin as a raw material for cosmetics", and the chromatographic conditions are as follows:

[0098] a) Chromatographic column: Z0RBAX StableBond C18, 4.6x250mm, 5um;

[0099] b) Flow rate: 1.0 mL / min;

[0100] c) Mobile phase: acetonitrile: water = 80:20, filtered with a 0.22 pm membrane filter;

[0101] d) Injection volume: 10uL;

[0102] e) Column temperature: 25℃;

[0103] f) Wavelength: 280nm.

[0104] 2. Reagents

[0105] Source of peony flower water: Trade name: FangYe5031 peony hydrosol, purchased from Shandong Fangye Biotechnology Co., Ltd., batch number: 20231231B5031; INCI: peony (PAEONIA SUFFRUTICOSA) flower water, parahydroxyacetophenone, 1,2-hexanediol; among them, the content of each component is: peony (PAEONIA SUFFRUTICOSA) flower water 99%, parahydroxyacetophenone 0.5%, 1,2-hexanediol 0.5%.

[0106] Example 1-Example 6: Preparation of glabridin composition

[0107] Recipe: See Table 1.

[0108] Table 1: Glabridin composition formula

[0109]

[0110] Preparation method:

[0111] (1) Mix glabridin and oil, heat to 70°C to dissolve, and mix evenly to obtain S1 phase;

[0112] (2) Mix 3-o-ethyl ascorbic acid, anionic surfactant, nonionic surfactant, polyol and water, heat to 60°C to dissolve, and mix well to obtain S2 phase;

[0113] (3) While stirring the S2 phase, adding the S1 phase obtained in step (1) to the S2 phase obtained in step (2), mixing, and forming a gel;

[0114] (4) The gel obtained in step (3) is mixed with S3 to obtain the glabridin composition.

[0115] Example 7-Example 11: Essence Dosage Form

[0116] Recipe: See Table 2.

[0117] Table 2: Essence dosage form formula

[0118]

[0119] Preparation method:

[0120] (1) Mix the components in phase A, heat to 80°C, keep warm for 30 minutes, stir until completely dissolved, and then cool to 45°C to obtain phase A;

[0121] (2) Mix the components in phase B, heat to 65°C, stir until completely dissolved, and then cool to room temperature to obtain phase B;

[0122] (3) Stir the components in phase C until they are completely dissolved to obtain phase C;

[0123] (4) Mix and stir the components in phase D, heat to 70°C, and homogenize at 2000 rpm for 10 minutes to obtain phase D;

[0124] (5) While stirring phase A, phases B, C, D, E and F are added to phase A obtained in step (1) and mixed to obtain the essence dosage form cosmetic product.

[0125] Comparative Examples 1-5: Glabridin Composition

[0126] Recipe: See Table 3.

[0127] Table 3: Glycyrrhizin composition formula of Comparative Examples 1 to 5

[0128]

[0129] Preparation method: Prepare according to the preparation method of Example 1, except that the component with a content of 0 is not added, and the other components are added according to the content of the corresponding components in each comparative example.

[0130] Comparative Examples 6-11: Investigation of Nonionic Surfactants

[0131] Recipe: See Table 4.

[0132] Table 4: Nonionic surfactant formulations investigated

[0133]

[0134] Preparation method: Prepare according to the preparation method of Example 1, except that the component with a content of 0 is not added, and the other components are selected and added according to the corresponding components of each comparative example.

[0135] Comparative Example 12-Comparative Example 14: Investigation of anionic surfactants

[0136] Recipe: See Table 5.

[0137] Table 5: Anionic surfactant formulations investigated

[0138]

[0139] Preparation method: Prepare according to the preparation method of Example 1, except that different anionic surfactants are used.

[0140] Comparative Example 15-Comparative Example 18: Investigation of Grease

[0141] Recipe: See Table 6.

[0142] Table 6: Investigation formula of oils and fats

[0143]

[0144] Preparation method: Prepare according to the preparation method of Example 1, except that different oils are used.

[0145] Comparative Examples 19-21: Investigation of Polyols

[0146] Recipe: See Table 7.

[0147] Table 7: Polyol formulations investigated

[0148]

[0149] Preparation method: Prepare according to the preparation method of Example 1, except that different polyols are used.

[0150] Comparative Example 22: Preparation Method Investigation

[0151] The formula of this comparative example is shown in Table 8.

[0152] Table 8: Comparative Example 22 Formulation

[0153]

[0154] Preparation method:

[0155] Compared with Example 1, the difference between this comparative example and Example 1 is that in the preparation method, the 3-o-ethyl ascorbic acid in phase S1 is added in step (4) instead. The detailed steps are as follows:

[0156] (1) Mix glabridin and oil, heat to 70°C to dissolve, and mix evenly to obtain S1 phase;

[0157] (2) Mix a nonionic surfactant, anionic surfactant, polyol and water, heat to 60°C to dissolve, and mix evenly to obtain S2 phase;

[0158] (3) While stirring the S2 phase, adding the S1 phase obtained in step (1) to the S2 phase obtained in step (2), mixing, and forming a gel;

[0159] (4) The gel obtained in step (3) is then mixed with the water and 3-o-ethyl ascorbic acid in phase S3 to obtain the glabridin composition.

[0160] Comparative Example 23: Preparation Method Investigation

[0161] The formula of this comparative example is shown in Table 9.

[0162] Table 9: Comparative Example 23 Formulation

[0163]

[0164] Preparation method:

[0165] The preparation method of this comparative example is different from the preparation method of Example 1 in that the order of adding components in the preparation method is different. The specific steps are as follows:

[0166] (1) Mix glabridin and oil, heat to 70°C to dissolve, and mix evenly to obtain S1 phase;

[0167] (2) Mix a nonionic surfactant, anionic surfactant, polyol and water, heat to 60°C to dissolve, and mix evenly to obtain S2 phase;

[0168] (3) While stirring the S2 phase, add the S1 phase obtained in step (1) to the S2 phase obtained in step (2), mix, and obtain a mixture (Note: no gel will be formed here);

[0169] (4) The mixture obtained in step (3) is then mixed with 3-o-ethyl ascorbic acid to obtain the glabridin composition.

[0170] Comparative Example 24: Cyclodextrin Dosage Form Investigation

[0171] Table 10: Comparative Example 24 Formulation

[0172]

[0173] Preparation method:

[0174] The S1 phase was completely dissolved by stirring at room temperature, and the S2 phase was completely dissolved by stirring at room temperature; the S1 and S2 phases were mixed and shaken at 200 r / min for 24 hours to obtain a clear and transparent solution; the ethanol was then removed by a rotary evaporator at 45°C, and the solution was then frozen in a -20°C refrigerator for 12 hours, and freeze-dried in a freeze dryer to obtain the glabridin composition of Comparative Example 24 (a cyclodextrin dosage form).

[0175] Comparative Example 25: Liposome Formulation Investigation

[0176] Table 11: Comparative Example 25 Formulation

[0177]

[0178] Preparation method:

[0179] The S1 phase was heated to 80°C and stirred to dissolve completely, and the S2 phase was heated to 80°C and stirred to dissolve completely; the S1 phase was added dropwise to the S2 phase, and the mixture was stirred continuously and emulsified at a high speed of 10000 rpm for 1 min to prepare a micron-sized dispersion; and the high-pressure homogenization was repeated 5 times at 1500 bar to prepare the glabridin composition (liposome dosage form) of Comparative Example 25.

[0180] Comparative Examples 26-50: Essence Formulation

[0181] Comparative Examples 1-25 were added to the formula of the essence dosage form, and the formula is shown in Table 12.

[0182] Table 12: Formulas for adding comparative examples 1-25 to the essence dosage form

[0183]

[0184] Preparation method: Prepare according to the preparation method of Examples 7-11, except that phase F is replaced with the glabridin compositions obtained in Comparative Examples 1-25, respectively, and the components are added according to the contents in Table 12.

[0185] Test Example 1: Permeability Test

[0186] Test Method:

[0187] (1) The essence dosage forms of Examples 7 to 9 and Comparative Examples 26, 47, 49 and 50 were taken respectively, and the permeation behaviors of the samples at 2 h, 4 h, 8 h, 12 h and 24 h were studied based on the suckling pig skin-Franz cell system according to "GB-T27818-2011 "In vitro test method for skin absorption of chemicals"" and "Q / FZR 0101-2023 "Glycyrrhizin as raw material for cosmetics"". See Table 13.

[0188] (2) The essence dosage forms obtained in Comparative Examples 27 to 46 and Comparative Example 48 were respectively taken and the permeation behavior of the samples was studied based on the suckling pig skin-Franzcell system for 24 hours. See Table 14.

[0189] This test set up 3 parallel groups and calculated the average value. The test results are shown in Table 13 and Table 14;

[0190] Table 13: Results of penetration performance at different times (ug / cm 2 )

[0191]

[0192] Table 14: 24h permeability test results / (ug / cm 2 )

[0193]

[0194] in conclusion:

[0195] (1) Compared with a formulation lacking any of 3-o-ethyl ascorbic acid, polyols, nonionic surfactants, and anionic surfactants, the glabridin composition provided by the present invention is more conducive to improving the permeability of the essence dosage form and has unexpected technical effects;

[0196] (2) Compared with other preparation methods (for example, the order of adding 3-o-ethyl ascorbic acid is different), the glabridin composition obtained by the preparation process provided by the present invention is more conducive to improving the permeability of the essence dosage form and has unexpected technical effects.

[0197] (3) Compared with cyclodextrin inclusion and liposome inclusion, the glabridin composition obtained by the preparation process provided by the present invention is more conducive to improving the permeability of the essence dosage form and has unexpected technical effects.

[0198] (4) Compared with other nonionic surfactants, the glabridin composition obtained by using oleth-20 and polyglycerol-10 oleate as nonionic surfactants in the present invention is more conducive to improving the permeability of the essence dosage form, and has unexpected technical effects.

[0199] (5) Compared with other polyols, the glabridin composition obtained by using 1,3-butanediol as the polyol in the present invention is more conducive to improving the permeability of the essence dosage form, and has unexpected technical effects.

[0200] (6) Compared with other oils, the glabridin composition obtained by using caprylic acid / capric acid triglyceride as the oil in the present invention is more conducive to improving the permeability of the essence dosage form, and has unexpected technical effects.

[0201] Test Example 2: Clinical whitening efficacy verification

[0202] Test method: Take the essence formulations of Examples 7 to 9 and Comparative Examples 26, 47, 49 and 50 respectively, and according to the "First Method Ultraviolet Induced Human Skin Melanization Model Whitening Efficacy Test Method", take the skin color visual score difference or ITA° difference or MI difference at any time point before and after the application of the test product, and compare it with the negative control. If there is a significant improvement (P<0.05), otherwise it is considered that the test product has no freckle removal and whitening effect. The test results are shown in Table 15.

[0203] Table 15: Results of the difference between the test product before and after application and the negative control

[0204]

[0205] in conclusion:

[0206] (1) Compared with the composition without adding 3-o-ethyl ascorbic acid, the glabridin composition provided by the present invention is more conducive to improving the onset rate and effect of the clinical whitening and freckle removal effect of the essence dosage form, and has unexpected technical effects;

[0207] (2) Compared with other preparation methods (for example, the order of adding 3-o-ethyl ascorbic acid is different), the glabridin composition obtained by the preparation process provided by the present invention is more conducive to improving the onset rate and effect of the clinical whitening and freckle removal effect of the essence dosage form, and has unexpected technical effects.

[0208] (3) Compared with cyclodextrin inclusion and liposome inclusion, the glabridin composition obtained by the preparation process provided by the present invention is more conducive to improving the onset rate and effect of the clinical whitening and freckle removal efficacy of the essence dosage form, and has unexpected technical effects.

[0209] Test Example 3: Investigation of state stability and content stability

[0210] Test method: According to ISO / TR 18811-2018 Cosmetics. Guidelines for Stability Tests of Cosmetics and Q / FZR0101-2023 "Glycyrrhizin as Raw Material for Cosmetics", the glycyrrhizin compositions prepared in the above examples and comparative examples were respectively placed at 45±2°C and -15±2°C to observe the stability for 6 months and test the glycyrrhizin content after 6 months (the content here represents the ratio of the measured concentration of glycyrrhizin in the product to the theoretical concentration multiplied by 100%) (the sampling and testing time points include 0 days, 7 days, 14 days, 1 month, 3 months and 6 months). The results are shown in Tables 16, 17 and 18. (Note: 1. Stop observation immediately when abnormal stability performance such as precipitation or stratification occurs, and " / " means that stability is not observed; 2. No content test will be performed on samples where crystal precipitation has been observed with the naked eye)

[0211] Table 16: Stability after 6 months at 45±2℃

[0212]

[0213] Table 17: Stability after 6 months at -15±2℃

[0214]

[0215] Table 18: Content stability

[0216]

[0217] in conclusion:

[0218] (1) Compared with a formulation lacking any one of 3-o-ethyl ascorbic acid, polyol, nonionic surfactant, and anionic surfactant, the formulation provided by the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high and low temperature conditions.

[0219] (2) Compared with other nonionic surfactants, the use of oleth-20 and polyglycerol-10 oleate in the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high and low temperature conditions.

[0220] (3) Compared with other polyols, the use of 1,3-butanediol in the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high temperature conditions.

[0221] (4) Compared with other oils, the use of caprylic acid / capric acid triglyceride in the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high temperature conditions.

[0222] (5) Compared with other anionic surfactants, the use of sodium stearoyl glutamate in the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high and low temperature conditions.

[0223] (6) Compared with other preparation methods (for example, different addition orders of 3-o-ethyl ascorbic acid or water), the preparation process provided by the present invention is more conducive to improving the state stability and content stability of the glabridin composition under high and low temperature conditions.

[0224] Test Example 4: pH stability study

[0225] Test method: According to "GB / T 13531.1-2008 "Determination of pH value of general test methods for cosmetics", the highly transdermal permeation-enhancing water-soluble glabridin compositions prepared in Examples 1-6 and Comparative Examples 1 and 22 were respectively taken to measure the pH at each stability placement time point (stability placement conditions and time are shown in Test Example 3), and the pH stability of the samples was tested. The results are shown in Table 19.

[0226] Table 19: pH stability test results

[0227]

[0228] Conclusion: It can be seen from Examples 1-6 and Comparative Example 22 that, compared with other preparation methods (for example, a different order of adding 3-o-ethyl ascorbic acid), the preparation process provided by the present invention is more conducive to improving the pH stability of the glabridin composition under high and low temperature conditions.

[0229] Test Example 5: Patch test

[0230] Test method: Take the glabridin compositions of Comparative Example 1 and Comparative Example 22 in Examples 1-6 and Test Example 1, respectively, and conduct skin occlusive patch tests according to the "Technical Specification for Safety of Cosmetics" (2015 Edition) Human Skin Patch Test (wherein the test samples are samples of 0 days, 45°C for 6 months, and -15°C for 6 months, respectively).

[0231] Test scoring criteria: See Table 20.

[0232] Test results: See Table 21.

[0233] Table 20: Scoring criteria

[0234]

[0235] Table 21: Test results

[0236]

[0237] in conclusion:

[0238] (1) Compared with not adding 3-o-ethyl ascorbic acid, the formula provided by the present invention is more conducive to improving the safety of the glabridin composition and has unexpected technical effects;

[0239] (2) Compared with other preparation methods (for example, the order of adding 3-o-ethyl ascorbic acid is different), the preparation process provided by the present invention is more conducive to improving the safety of the glabridin composition.

[0240] The method of the present invention has been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein within the content, spirit and scope of the present invention to implement and apply the technology of the present invention. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention.

Claims

1. A glabridin composition, characterized in that: The glabridin composition is prepared from an S1 phase, an S2 phase and an S3 phase, wherein the S1 phase is composed of oil and glabridin, the S2 phase is prepared from 3-o-ethyl ascorbic acid, an anionic surfactant, a nonionic surfactant, a polyol and water, and the S3 phase is water; The nonionic surfactants are oleth-20 and polyglycerol-10 oleate; The anionic surfactant is sodium stearoyl glutamate; The oil is caprylic / capric triglyceride; The polyol is 1,3-butanediol; Calculated based on the total mass of the glabridin composition, the content of the glabridin is 0.10wt%-4.00wt%, the content of the 3-o-ethyl ascorbic acid is 0.10wt%-4.00wt%; the total content of the nonionic surfactant is 0.70wt%-10.00wt%, the content of the oil is 1.00wt%-40.00wt%; the content of the polyol is 0.60wt%-6.00wt%, the content of the anionic surfactant is 0.10wt%-1.00wt%, the content of water in the S2 phase is 0.30wt%-3.00wt%, and the balance is the S3 phase; The preparation method of the glabridin composition comprises the following steps: (1) Mix glabridin and oil, heat to dissolve, and mix evenly to obtain S1 phase; (2) Mix 3-o-ethyl ascorbic acid, anionic surfactant, nonionic surfactant, polyol and water, heat to dissolve, and mix evenly to obtain S2 phase; (3) While stirring the S2 phase, adding the S1 phase obtained in step (1) to the S2 phase obtained in step (2), mixing, and forming a gel; (4) The gel obtained in step (3) is mixed with S3 to obtain the glabridin composition.

2. The glabridin composition according to claim 1, wherein, based on the total mass of the glabridin composition, the content of oleth-20 is 0.10wt%-4.00wt%, and the content of polyglycerol-10 oleate is 0.60wt%-6.00wt%.

3. The glabridin composition according to claim 1, calculated based on the total mass of the glabridin composition, the content of glabridin is 1.00wt%-4.00wt%, the content of 3-o-ethyl ascorbic acid is 1.00wt%-4.00wt%; the content of oleth-20 is 0.50wt%-4.00wt%, the content of polyglycerol-10 oleate is 6.00wt%, the content of oil is 10.00wt%-40.00wt%; the content of the polyol is 6.00wt%, the content of the anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase; or Calculated based on the total mass of the glabridin composition, the content of the glabridin is 0.10wt%, the content of the 3-o-ethyl ascorbic acid is 0.10wt%; the content of the oleth-20 is 0.10wt%, the content of the polyglycerol-10 oleate is 0.60wt%, the content of the oil is 1.00wt%; the content of the polyol is 0.60wt%, the content of the anionic surfactant is 0.10wt%, the content of water in the S2 phase is 0.30wt%, and the balance is the S3 phase.

4. The glabridin composition according to claim 1, wherein, based on the total mass of the glabridin composition, the content of glabridin is 1.00wt%, the content of 3-o-ethyl ascorbic acid is 1.00wt%, the content of oleth-20 is 0.50wt%, the content of polyglycerol-10 oleate is 6.00wt%, the content of oil is 10.00wt%, the content of polyol is 6.00wt%, the content of anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase; or Calculated based on the total mass of the glabridin composition, the content of the glabridin is 1.00wt%, the content of the 3-o-ethyl ascorbic acid is 1.00wt%; the content of the oleth-20 is 1.00wt%, the content of the polyglycerol-10 oleate is 6.00wt%, the content of the oil is 10.00wt%; the content of the polyol is 6.00wt%, the content of the anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase; or Calculated based on the total mass of the glabridin composition, the content of the glabridin is 1.00wt%, the content of the 3-o-ethyl ascorbic acid is 2.00wt%; the content of the oleth-20 is 0.50wt%, the content of the polyglycerol-10 oleate is 6.00wt%, the content of the oil is 10.00wt%; the content of the polyol is 6.00wt%, the content of the anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase; or Calculated based on the total mass of the glabridin composition, the content of the glabridin is 2.00wt%, the content of the 3-o-ethyl ascorbic acid is 2.00wt%; the content of the oleth-20 is 2.00wt%, the content of the polyglycerol-10 oleate is 6.00wt%, the content of the oil is 20.00wt%; the content of the polyol is 6.00wt%, the content of the anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase; or Calculated based on the total mass of the glabridin composition, the content of the glabridin is 4.00wt%, the content of the 3-o-ethyl ascorbic acid is 4.00wt%; the content of the oleth-20 is 4.00wt%, the content of the polyglycerol-10 oleate is 6.00wt%, the content of the oil is 40.00wt%; the content of the polyol is 6.00wt%, the content of the anionic surfactant is 1.00wt%, the content of water in the S2 phase is 3.00wt%, and the balance is the S3 phase.

5. The glabridin composition according to claim 1, wherein the heating to dissolve in step (1) is heating to 60°C-80°C for dissolution. 6 . The glabridin composition according to claim 1 , wherein the heating to dissolve in step (2) is heating to 60° C.-70° C. for dissolution.

7. The glabridin composition according to claim 1, wherein the heating and dissolving in step (1) is heating to 70°C for dissolving; and the heating and dissolving in step (2) is heating to 60°C for dissolving.

8. The glabridin composition according to claim 1, wherein the mass ratio of water to polyol in step (2) is 1:1-1:

2.

9. Use of the glabridin composition according to any one of claims 1 to 8 in the preparation of cosmetics.

10. A cosmetic comprising the glabridin composition according to any one of claims 1 to 8.

Citation Information

Patent Citations

  • Plant compound whitening agent submicron plasmids as well as preparation method and application thereof

    CN105193636A

  • Fat-soluble glabridin compound whitening agent and application thereof

    CN108498412A

  • Multi-protection glabridin carrier as well as preparation method and application thereof

    CN116869846A

  • Oil-in-water emulsifier, application thereof and daily chemical product

    CN117064771A

  • Compositions comprising macromolecular assemblies of lipid and surfactant

    US20100062067A1